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Simple Summary: Meningioma are the most common primary intracranial tumour, yet gaps in
their molecular characterisation persist and effective treatments for aggressive, recurring, high-grade
(WHO grade III) meningioma are lacking. The aim of our study was to outline differences in
the molecular landscape between high-grade and low-grade (WHO grade I) meningioma by
combining transcriptomic and proteomic data from two former independent studies. We described
both concordant and discordant differential expression between grades and validated expression
at either the transcript or protein level for genes including MAOB, CST3, LAMP2, PACS1 and
HTRA1. Concordantly upregulated transcripts/proteins of high-grade tumours were enriched in
biological processes such as oxidative phosphorylation and RNA metabolism. Using an integrated
omics approach we have provided a previously unreported, valuable insight into the altered
transcript/protein expression profiles between high and low-grade meningioma. In addition,
our findings identified molecules that may hold potential as biomarkers or therapeutic targets
of high-grade meningioma.
Abstract: Meningioma are the most frequent primary intracranial tumour. Management of
aggressive meningioma is complex, and development of effective biomarkers or pharmacological
interventions is hampered by an incomplete knowledge of molecular landscape. Here, we present
an integrated analysis of two complementary omics studies to investigate alterations in the
“transcriptome–proteome” profile of high-grade (III) compared to low-grade (I) meningiomas.
We identified 3598 common transcripts/proteins and revealed concordant up- and downregulation in
grade III vs. grade I meningiomas. Concordantly upregulated genes included FABP7, a fatty acid
binding protein and the monoamine oxidase MAOB, the latter of which we validated at the protein
level and established an association with Food and Drug Administration (FDA)-approved drugs.
Notably, we derived a plasma signature of 21 discordantly expressed genes showing positive changes
in protein but negative in transcript levels of high-grade meningiomas, including the validated genes
CST3, LAMP2, PACS1 and HTRA1, suggesting the acquisition of these proteins by tumour from plasma.
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Aggressive meningiomas were enriched in processes such as oxidative phosphorylation and RNA
metabolism, whilst concordantly downregulated genes were related to reduced cellular adhesion.
Overall, our study provides the first transcriptome–proteome characterisation of meningioma,
identifying several novel and previously described transcripts/proteins with potential grade III
biomarker and therapeutic significance.
Keywords: meningioma; transcriptomics; proteomics; data integration; biomarker; drug
targets; MAOB
1. Introduction
Meningioma arise from the meninges, the tissue layers that envelop the brain and spinal
cord, and account for approximately 36% of all primary central nervous system (CNS) tumours [1].
According to the current WHO classification, around 80% of meningiomas are benign (grade I),
20–25% atypical (grade II) and 1–6% malignant (grade III) [1]. Standard treatment is surgical
resection and can be curative [2]. However, excision is not without risk of postoperative morbidity,
and, dependent upon location, tumours may be incompletely resected or surgically inaccessible [2].
Here, radiotherapy is recommended as either adjunct or monotherapy, whilst chemotherapy is
ineffective in meningioma [3]. Notably, therapeutic management following surgical removal of WHO
grade III cranial meningioma remains challenging, with a 5-year survival of just 30% in comparison
to 80% for WHO grade II and 90% for WHO grade I tumours [4]. Furthermore, de novo WHO grade
III anaplastic meningiomas have been found to be associated with a dismal mean overall survival of
3.1 years [5].
Recent studies have started to unravel the molecular landscape of meningioma. In addition to
the established association of meningioma with pathogenic aberrations in the tumour suppressor
gene NF2, genomic analyses have identified genes including TRAF7, KLF4, AKT1, SMO, PIK3CA and
POLR2A to possess recurrent mutations in low grade non-NF2 mutant meningioma [6–9]. Specific to
grade III meningioma, somatic driver mutations in the SWI/SNF chromatic regulatory complex, most
frequently in the SWI/SNF component AIRD1A, have recently been revealed and linked to poor
prognosis [10]. Transcriptomic profiling of meningioma grades has further facilitated the discovery of
candidate genes displaying prognostic potential [11–15]. Notably, Schmidt et al. (2016) performed a
comparative transcriptomic analysis across all grades comprising the largest cohort of rare grade III
meningioma to date [12]. Although the study provided comprehensive coverage of the transcriptional
meningioma landscape and identified PTTG1 and LEPR as prognostic markers of aggressive behaviour,
it remained to be demonstrated whether the transcriptional changes observed were generally indicative
of changes in protein abundance. Since proteins exert the intended function of a majority of genes,
it is important to assess the predictive value of an altered transcriptomic profile at the protein level.
Moreover, proteins are subject to many post-translational modifications undetectable at the transcript
level, such as phosphorylation, which regulate protein structure, functional state and subcellular
compartmental localisation. Previous integrations of transcriptomic and proteomic profiles generated
from mammalian cell lines, including some cancer cell lines, have shown a general overall correlation
of transcript and protein levels despite notable differences [16–18].
Proteomic profiling studies in meningioma have enabled the grade-wise comparison of differential
expression patterns as well as the identification of promising biomarkers or therapeutic targets [19,20].
However, it has become apparent that the integration of different omics approaches is necessary to
gain a more complete picture of the molecular alterations underlying a complex pathology than the
analysis of individual omics datasets can provide [21]. Indeed, several recent studies have utilised
multiple omics platforms with varying levels of data integration to reveal a comprehensive molecular
understanding of meningioma pathogenesis. Sahm et al. (2017) described a DNA methylation-based
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meningioma classification system demonstrating greater improved accuracy for predicting recurrence
and prognosis than the WHO grade alone and went on to characterise the system by DNA copy number
analysis, mutational profiling and RNA sequencing [22]. Interestingly, grade III meningioma mapped
into two distinct methylation classes associated with differing progression-free survival outcomes [22].
Additional studies have identified further molecular signatures attributed with high-grade meningioma
by integration of genomic analyses, including upregulation of the FOXM1 transcription factor network,
an upregulation of HOX genes and mutations of the SWI/SNF chromatin regulatory complex [10,23–25].
Nevertheless, a proteomic dataset has yet to be incorporated into a multi-omics approach.
In the present study, we integrated two former independent but comparable meningioma omics
datasets covering the transcriptome and proteome to compare the molecular states of grade I and grade
III meningioma [12,19]. Both datasets stand out as providing the largest cover of grade III meningioma
to date. We identified coherent patterns in transcriptomic and proteomic profiles, revealed common
functional trends in the combined datasets and elucidated upon underlying causes of discordant
expression between datasets. Our findings might not only assist in the interpretation of transcriptomic
studies and boost their predictive power but also provide clues about the type of dysregulated
expression observed in meningioma.
2. Results
2.1. Integrated Transcriptome–Proteome Analysis of Grade III vs. Grade I Meningioma
To obtain a more comprehensive view of the molecular changes in meningiomas of different grades,
we integrated previously published proteomic measurements [19] with an extended meningioma
transcriptomic dataset [12]. Here, we focused on comparing the transcriptome–proteome of grade III
vs. grade I meningioma in order to dissect the altered molecular signature of the most aggressive
meningioma subgroup. Additionally, the integration allowed us to investigate concordant as well as
discordant alterations within the transcriptome–proteome dataset. We detected 3598 genes common to
both omics datasets following the mapping of transcripts and proteins to Entrez Gene IDs. For the shared
genes, we calculated grade III vs. grade I meningioma log2 fold changes (LFC) (Figure 1a; Table S3A).
Comparison of the transcriptomic and proteomic LFC distributions showed notable differences in spread
and mean (Figure S1). Proteins displayed a greater LFC range and a mean of 0.41 while transcript LFCs
exhibited a narrower range with a mean of 0.0. The divergence observed here could be due to differences
in underlying data processing and normalisation methods. Despite these differences, mRNA and protein
levels displayed a highly significant positive Pearson’s correlation coefficient of 0.35 (p = 3.6 × 10−104
Figure 1a). Nevertheless, the difference observed in dataset distributions warranted caution indicating
that direct integration of datasets based on original LFC values would not be suitable and may lead to
systematic biases. Therefore, we employed a rank-based integration approach that is robust against the
observed variation in LFC distribution (Table S3A). This approach enabled the definition of concordant
and discordant expression of the grade III meningioma transcriptome–proteome (see Materials and
Methods). The top 10 genes showing increased or decreased concordant differential expression between
grade III vs. grade I meningioma at both transcript and protein level are highlighted in Figure 1a. Further,
assigned transcript/protein rank and average rank value of the top 10 concordantly upregulated or
downregulated genes are presented in Figure 1b,c. Among the top genes with concordant upregulated
expression was the known oncogene AGR2 with the lowest average rank of 2.5, a transcript LFC of 2.39
and protein LFC of 4.73, as well as FABP7, which had an average rank of 4, a transcript LFC of 1.63 and
protein LFC of 6.68 (Figure 1b). Concordantly downregulated genes included FBLN1, which encodes
the extracellular glycoprotein fibulin-1 (FLBN1), with the highest average rank of 3590.5, a transcript
LFC of −2.16 and protein LFC of −3.88. We also detected the leptin receptor, LEPR, to be downregulated
in grade III meningioma, consistent with previous findings of its reduced abundance in higher
grade compared to low-grade meningiomas by Schmidt et al. (2016) and Menghi et al. (2011) [12,26].
Further, concordantly downregulated genes included MFAP4, a member of the microfibrillar-associated
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protein family, MFAP, which presented an average rank of 3575.5, a transcript LFC of −1.61 and protein
LFC of −3.62 (Figure 1c).Cancers 2020, 12, x FOR PEER REVIEW 4 of 24 
 
 
Figure 1. Concordant transcriptome–proteome differential expression of grade III vs. grade I 
meningiomas. (a) Scatterplot displaying 3598 genes commonly identified in a transcriptomic 
microarray analysis including 13 non-recurrent grade I meningiomas and 20 malignant grade III 
meningiomas and a global proteomic analysis including eight grade I and six grade III meningiomas 
[12,19]. Pearson’s correlation coefficient revealed a modest, yet highly significant correlation of r = 
0.35, p = 3.6 × 10−104. Log2 fold changes (LFC) at the transcript and protein level of overlapping genes 
are shown for grade III vs. grade I meningiomas. The top 10 genes based on average rank value 
exhibiting concordantly increased or decreased LFC between the two datasets are highlighted in red 
or green, respectively. (b,c) Top 10 genes showing concordantly increased (b) or decreased (c) LFC in 
Figure 1. Concordant transcriptome–proteome differential expression of grade III vs. grade I
meningiomas. (a) Scatterplot displaying 3598 genes commonly identified in a transcriptomic microarray
analysis including 13 non-recurrent grade I meningiomas and 20 malignant grade III meningiomas
and a global proteomic analysis including ight grade I and six grade III eni giom s [12,19].
Pearson’s correlation coefficient revealed modest, yet hi ly significant corr lation of r = 0.35,
p = 3.6 × 10−104. Log2 fold changes (LFC) at the transcript and protein level of overlapping genes are
shown for grade III vs. grade I meningiomas. The top 10 genes based on average rank value exhibiting
concordantly increased or decreased LFC between the two datasets are highlighted in red or green,
respectively. (b,c) Top 10 genes showing concordantly increased (b) or decreased (c) LFC in grade III
vs. grade I meningiomas are presented with respective LFC, rank and average rank values. Table S3A
provides details of all 3598 genes common to both analyses, transcript/protein LFC, their rank and
average rank.
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Next, we explored discordant transcriptome–proteome differential expression. This approach
enabled us firstly to prevent dismissal of potential targetable proteins exhibiting high protein LFC but
low transcript LFC in grade III vs. grade I meningiomas, and secondly, to investigate possible inhibition
of tumour suppressor translation in grade III compared to grade I displaying low protein LFC but a high
transcript LFC. Again, a rank-based approach was utilised to identify genes with profound discordant
expression (Figure 2a; Table S3B). The 10 genes ranked with the strongest discordant differential
expression demonstrating either a subtle transcript LFC and strong positive protein LFC (high average
rank value) or a positive transcript LFC and negative protein LFC (low average rank value) are
shown in Figure 2b,c. Discordant genes with a high average rank included SLC4A4, which encodes a
Na+/HCO3- co-transporter with a transcript LFC of −0.92 and protein LFC of 4.28, as well as ACS1,
which encodes the phosphofurin acidic cluster sorting protein-1, found to have −0.51 transcript LFC
and 3.34 protein LFC (Figure 2b). Displaying the lowest average rank (107.5) among discordant genes
was the linker histone H1.2 gene, HIST1H1C, with a transcript LFC of 1.24 and protein LFC of −1.61
(Figure 2c). In addition, NPTX1, known to promote neurite outgrowth, showed a low average rank of
112.5 with a 1.69 transcript LFC and −1.44 protein LFC (Figure 2c).
To explore discordant differential expression, we focused on a possible cause that could lead to
observing negative transcript LFC but high protein LFC in grade III meningioma compared to grade
I. Here, we hypothesised that increased protein levels may result from the plasma via the tumour
vasculature and thus do not need to be correlated with increased transcript levels within the tissue.
As both datasets integrated in this study captured transcripts and proteins derived not only from
tumour cells but also the tumour microenvironment, we can presume that a proportion of identified
proteins may have originated from the plasma. This possibility is further supported by the observation
that meningiomas tend to be highly vascularised brain tumours [27]. We therefore overlapped a
publicly accessible human plasma proteome reference set comprising 1929 canonical protein sequences
with the top 100 discordantly expressed genes showing positive protein LFC but negative transcript
LFC based on average rank (Table S3C) [28]. Following this, we identified 21 common proteins that
have previously been found in human plasma, including myelin basic protein (MBP), phosphofurin
acidic cluster sorting protein 1 (PACS1), amyloid-beta precursor protein (APP), desmoplakin (DSP)
and lysosome-associated membrane glycoprotein 2 (LAMP2) (Table 1).
2.2. Functional Annotation of Grade III vs. Grade I Meningioma Differential Transcriptome–Proteome Expression
Functional annotation analyses were performed to elucidate signalling pathways and biological
processes associated with differentially expressed transcripts/proteins. We submitted the 3598 transcripts
and proteins with corresponding LFCs to Gene Set Enrichment Analysis (GSEA) to identify overlapping
enriched Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways and gene ontology (GO) terms
(Table S4). Following KEGG pathway analysis, we observed 22 pathways with a positive normalised
enrichment score (NES) in both datasets suggesting their enrichment in grade III compared to grade I
meningioma (Figure 3a; Table S4A). Among pathways with the highest NES were numerous metabolic
processes: “oxidative phosphorylation” (77 genes), “aminoacyl tRNA biosynthesis” (31 genes),
“citrate cycle TCA cycle” (27 genes), “purine metabolism” (54 genes), “pyrimidine metabolism”
(33 genes) and “alanine, aspartate and glutamate metabolism” (18 genes). We identified 47 pathways
with a negative transcript and protein NES implying their downregulation in grade III meningioma vs.
grade I (Figure 3a; Table S4A). Several pathways displaying negative NES were associated with aspects
of the immune system such as “leukocyte transendothelial migration” (53 genes), “antigen processing
and presentation” (31 genes), “FcγR-mediated phagocytosis” (48 genes) and “complement and
coagulation cascades” (40 genes). Among the remaining pathways showing negative NES were
those surrounding cellular adhesions including “adherens junction” (36 genes), “regulation of actin
cytoskeleton” (105 genes), “tight junction” (54 genes) and “gap junction” (41 genes). To obtain a
more comprehensive coverage of the functional composition of meningioma molecular pathogenesis,
we applied a less stringent false discovery rate (FDR) of <0.2 to transcript and protein NESs across
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enrichment analyses. Note, an FDR threshold of <0.2 in both the transcriptomic and proteomic
enrichment analyses corresponds to a combined p-value < 0.04 for the simultaneous observation of
significant enrichment at both transcriptomic and proteomic level due to the multiplicative nature of
probabilities. Subsequent to relaxation of the FDR threshold, six of the 22 upregulated KEGG pathways
remained and are highlighted in Figure 3a. Again, we observed “oxidative phosphorylation” and
“aminoacyl tRNA biosynthesis” suggesting that pathways related to metabolism are strongly enriched
at both the transcriptome and proteome levels in grade III meningioma. Although only seven of the
48 downregulated pathways harboured an FDR < 0.2, these included pathways related to the previously
identified biological themes of cellular adhesion with “cell adhesion molecules (CAMs)” (50 genes)
and of the immune system with “leukocyte transendothelial migration” and “antigen processing and
presentation” pathways all significantly reduced in grade III vs. grade I meningiomas (Figure 3a).
This observation confirms recent findings based on RNA-seq data and tissue staining by Viaene and
colleagues that immune activity is increased in grade I compared to grade II or III meningioma [13].Cancers 2020, 12, x FOR PEER REVIEW 6 of 24 
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Figure 2. Discordant transcriptome–proteome differential expression of grade III vs. grade I
meningiomas. (a) Scatterplot displaying 3598 genes commonly identified in a transcriptomic microarray
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analysis including 13 non-recurrent grade I meningiomas and 28 malignant grade III meningiomas and
a global proteomic analysis including eight grade I and six grade III meningiomas [12,19]. Log2 fold
changes (LFC) at the transcript and protein level of overlapping genes are shown for grade III vs. grade
I meningioma. The top 10 genes based on average rank value exhibiting either a negative transcript LFC
and positive protein LFC (high average rank value) or a positive transcript LFC and negative protein
LFC (low average rank value) are highlighted in yellow and blue, respectively. (b,c) Top 10 genes
showing discordant differential expression with negative transcript LFC and positive protein LFC (b) or
positive transcript LFC and negative protein LFC (c) in grade III vs. grade I meningiomas are presented
with respective LFC, rank and average rank values. Table S3B provides details of all 3598 genes common
to both analyses, transcript/protein LFC, their discordant rank value and average rank. Protein LFC
values were ranked in ascending order (lowest LFC assigned rank of 1), transcript LFC values ranked
in descending order and average rank calculated.Cancers 2020, 12, x FOR PEER REVIEW 10 of 24 
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Figure 3. F nctional a notation of gra I vs. grade I meningioma transcriptome–proteome.
(a) Kyoto Encyclopaedia of Genes and Ge es (KE G) pathway analysis and (b) gene ontology (GO)
analysis of cellular component terms presenting enriched pathways/cellular components overlapping
between transcript and protein datasets. Bubble plots show normalised enrichment scores (NES) of
pathways/cellular components derived from Gene Set Enrichment Analysis (GSEA) of genes ranked
by transcript and protein LFCs. Size nd colour of each bubble epresent the number of differentially
expressed genes enriched in the pathway and the combined transcript and protein NES, respectively.
Highlighted are pathways/cellular components with false discovery rate (FDR) < 0.2 for both transcript
and protein NES. Table S4 details KEGG pathway a d O cellular component output.
In addition to annotation with enriched KEGG pathways, we performed GO cellular component
analysis to characterise the localisation of differentially expressed gene products within the cellular
anatomy. Among 84 terms xhibiting concordant positive NESs, 19 harboured significant enrichment
(FDR < 0.2) with over half of these related to mitochondria including “mitochondrial envelope”,
“mitochondrial matrix”, “respiratory chain” and “NADH dehydrogenase complex” (Figure 3b;
Table S4B). These findings were analogous to our previous pathway observations comprising many
enriched metab lic processes (Figure 2a). Remaining cellular components found to be significantly
enriched among upregulated transcripts/proteins of grade III meningioma were largely associated
with ribosomes. GO analysis revealed 85 terms demonstrating concordant negative NESs of both
downregulated transcripts and proteins (Table S4B). Eight terms were classed as significant (FDR < 0.2)
of which t lea t two i icated a decline cytoskel al orga isation s ch s “ ctin cytoskeleton”
(200 genes) and “actin filament bundle” (31 genes) (Figure 3b).
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Table 1. Twenty-one of the top 100 discordantly expressed genes (positive protein LFC but negative transcript LFC) also found to be present in the published Human
Plasma Peptide Atlas consisting of 1929 canonical protein sequences [28]. Shown are overlapping genes with respective LFC, rank and average rank values. Table S3C
details discordantly expressed proteins also identified in the human plasma proteome reference set.
Gene Symbol Protein Name LFC Transcript Rank Transcript LFC Protein Rank Protein Average Rank
MBP Myelin basic protein −1.21 3521 2.05 3234 3377.5
PACS1 Phosphofurin acidic cluster sortingprotein 1 −0.51 3218 3.34 3534 3376
APP Amyloid-beta precursor protein −0.77 3395 2.26 3318 3356.5
DSP Desmoplakin −1.43 3544 1.48 2938 3241
FCGBP IgGFc-binding protein −0.46 3156 2.11 3264 3210
LAMP2 Lysosome-associated membraneglycoprotein 2 −0.71 3369 1.64 3043 3206
BOLA2B BolA-like protein 2 −0.28 2823 3.30 3532 3177.5
PTPRF Receptor-type tyrosine-proteinphosphatase F −1.03 3487 1.33 2828 3157.5
DCN Decorin −0.77 3400 1.39 2875 3137.5
AK3 GTP:AMP phosphotransferase AK3,mitochondrial −0.51 3219 1.58 3006 3112.5
HTRA1 Serine protease HTRA1 −1.47 3550 1.12 2670 3110
OGN Mimecan −0.89 3445 1.19 2731 3088
GOLIM4 Golgi integral membrane protein 4 −0.73 3379 1.25 2771 3075
LAMB2 Laminin subunit beta-2 −0.64 3331 1.29 2799 3065
ITM2B Integral membrane protein 2B −0.63 3319 1.24 2766 3042.5
SDHB Succinate dehydrogenase [ubiquinone]iron-sulfur subunit, mitochondrial −0.31 2870 1.90 3175 3022.5
CST3 Cystatin-C −0.38 3034 1.51 2962 2998
LTBP4 Latent-transforming growth factorbeta-binding protein 4 −0.53 3239 1.21 2745 2992
PPP3CA Serine/threonine-protein phosphatase 2Bcatalytic subunit alpha isoform −0.54 3245 1.15 2694 2969.5
HEXA Beta-hexosaminidase subunit alpha −0.27 2765 1.87 3163 2964
PCSK1N ProSAAS −0.83 3426 0.91 2483 2954.5
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2.3. Validation of Concordant and Discordant Expression in Grade III Meningioma
Subsequent to our integrated transcriptome–proteome analysis and functional annotation of grade
III vs. grade I meningioma, we chose to validate a subset of concordant and discordant transcript/protein
expression using, where available, an independent sample cohort of meningioma tissue. In addition,
we endeavoured to select candidates for experimental validation that to date had not yet been explored
in meningiomas or where previously studied, demonstrated a conflicting observation to our data
presented here and thus we investigated further using an alternative technique. First, we validated
the concordant differential expression of monoamine oxidase type B (MAOB) (transcript LFC 0.7,
protein LFC 3.19), fatty acid-binding protein 7 (FABP7) (transcript LFC 1.63, protein LFC 6.68) and
retinol-binding protein 1 (RBP1) (transcript LFC 1.12, protein LFC 3.44) at the protein level by Western
blot (WB) using an independent cohort of five meningioma tissues of both grade I and grade III.
We observed an average overexpression of ~37 folds for MAOB and ~eight folds for FABP7 in
grade III tumours compared to grade I, whilst RBP1 average grade III expression was analogous
to that of grade I (Figure 4a). WB validation displayed varying immunoreactivity across samples,
indicating some underlying heterogeneity of meningioma (Figure 4a). In addition to WB, we performed
experimental validation of these concordantly expressed proteins by immunohistochemistry (IHC).
Importantly, this technique allowed us to expand the sample cohorts to comprise of 10 sections per
grade. MAOB showed a distinct increase in expression in grade III meningiomas consistent with WB
findings, generally displaying moderate immunostaining, whereas grade I tumours showed either
weak or absent expression (Figure 4b; Table S5). Here, it is important to note that as our validation
studies were performed on tumour tissue, any expression observed for our candidate proteins may not
solely have originated from meningioma cells but also from cells of the tumour stroma. As an example,
we stained the grade III meningioma, J10, for the common macrophage marker, CD68 (Figure S2).
Although we detected some CD68+ cells, the widespread expression of MAOB throughout the tissue
suggests that the majority of immunostaining is genuinely derived from meningioma cells themselves.
FABP7 and RBP1 immunostaining were detected but variable within each grade and demonstrated no
clear difference between the grades (Figure 4b; Table S5). Next, we performed RT-qPCR in seven grade
III vs. seven grade I meningioma tissues to validate discordant differential expression at the transcript
level of selected genes that exhibited negative transcript but high protein LFC and were identified in
a human plasma proteome reference set. Following RT-qPCR, we identified a significant reduction
in relative expression for CST3, LAMP2, PACS1 and HTRA1 in grade III meningioma compared with
grade I compatible with our hypothesis that increased abundance of these proteins in the tumour
originates from the blood circulation (Figure 4c–f).
2.4. Drug–Gene Interaction Analysis
In order to identify Food and Drug Administration (FDA)-approved drugs predicted to interact
with any of the 3598 proteins of our transcriptome–proteome analysis, we utilised the drug prediction
database, DGIdb [29]. Although many pure transcriptomic analyses have previously harvested genes
with promise as therapeutic targets of meningioma, confirmation of simultaneous dysregulation
of protein expression is frequently missing. As protein abundance correlates but does not fully
mirror transcript abundance, the value of drug target prediction based on transcriptomic data
therefore warrants caution. We reasoned that by focusing on transcripts/proteins with concordant
upregulation in grade III meningioma across both datasets, we were able to identify candidates with
the strongest potential as drug targets. Following submission of the 3598 proteins to the DGIdb,
685 proteins, approximately 20%, were found to interact with one or more FDA-approved drugs
and, of these, 264 displayed a concordant increase in transcript and protein expression in grade III
vs. grade I meningiomas (Table S6). In addition to the previously validated proteins MAOB and
RBP1, proteins displaying strong concordantly increased expression associated with FDA-approved
drugs included the calcium and zinc-binding protein S100-A8 (S100A8), microtubule proteins tubulin
beta-3 chain (TUBB3) and tubulin beta-2B chain (TUBB2B), carbonic anhydrase 2 (CA2), involved in
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maintaining pH homeostasis and multiple subunits of respiratory complex I such as NDUFAB1,
NDUFS2 and NDUFB9 (Figure 5; Table S6).
Cancers 2020, 12, x FOR PEER REVIEW 11 of 24 
 
our candidate proteins may not solely have originated from meningioma cells but also from cells of 
the tumour stroma. As an example, we stained the grade III meningioma, J10, for the common 
macrophage marker, CD68 (Figure S2). Although we detected some CD68+ cells, the widespread 
expression of MAOB throughout the tissue suggests that the majority of immunostaining is genuinely 
derived from meningioma cells themselves. FABP7 and RBP1 immunostaining were detected but 
variable within each grade and demonstrated no clear difference between the grades (Figure 4b; Table 
S5). Next, we performed RT-qPCR in seven grade III vs. seven grade I meningioma tissues to validate 
discordant differential expression at the transcript level of selected genes that exhibited negative 
transcript but high protein LFC and were identified in a human plasma proteome reference set. 
Following RT-qPCR, we identified a significant reduction in relative expression for CST3, LAMP2, 
PACS1 and HTRA1 in grade III meningioma compared with grade I compatible with our hypothesis 
that increased abundance of these proteins in the tumour originates from the blood circulation 
(Figure 4c–f). 
 
Figure 4. Validation of concordantly and discordantly expressed differentially expressed proteins and 
transcripts in grade III vs. grade I meningiomas. (a) Western blot (WB) analysis of the proteins MAOB, 
FABP7 and RBP1 that demonstrated a concordant increase in expression following transcriptome–
proteome integration in meningioma tissue lysates. WB quantification of average densities of MAOB, 
FABP7 and RBP1 in grade III meningioma compared to average densities in grade I is shown. GAPDH 
was used as loading control. Grade I n = 5, grade III n = 5. (b) Immunohistochemistry validation of 
MAOB, FABP7 and RBP1. Representative images show immunohistochemical staining in grade I and 
grade III meningioma. Table S5 details the full list of specimens and corresponding semi-quantitative 
assessment. Grade I n = 10, grade III n = 10. RT-qPCR validation of discordantly expressed transcripts 
(c) CST3 (d) LAMP2 (e) PACS1 and (f) HTRA1 that exhibited negative transcript but positive protein 
LFC in grade III meningioma compared to grade I following transcriptome–proteome integration. 
Grade I n = 7, grade III n = 7. Statistical significance was determined by Mann–Whitney test * p ≤ 0.05; 
*** p ≤ 0.001. 
2.4. Drug–Gene Interaction Analysis 
In order to identify Food and Drug Administration (FDA)-approved drugs predicted to interact 
with any of the 3598 proteins of our transcriptome–proteome analysis, we utilised the drug prediction 
Figure 4. Validation of concordantly and discordantly expressed differentially expressed proteins
and transcripts in grade III vs. grade I meningiomas. (a) Western blot (WB) analysis of the
proteins MAOB, FABP7 and RBP1 that demonstrated a concordant increase in expression following
transcriptome–proteome i tegration i meningioma tissue lysates. WB quantification of average
densities of MAOB, FABP7 and RBP1 in grade III meningioma compared to average densities in grade I
is shown. GAPDH was used as loading control. Grade I n = 5, grade III n = 5. (b) Immunohistochemistry
validation of MAOB, FABP7 and RBP1. Representative images show immunohistochemical staining
in grade I and grade III meningioma. Table S5 details the full list of specimens and corresponding
semi-quantitative ass ssment. Grade I n = 10, gra III n = 10. RT-qPCR validation of discordantly
expressed transcripts (c) CST3 (d) LAMP2 (e) PACS1 and (f) HTRA1 that exhibited negative transcript but
positive protein LFC in grade III meningioma compared to grade I following transcriptome–proteome
integration. Grade I n = 7, grade III n = 7. Statistical significance was determined by Mann–Whitney
test * p ≤ 0.05; *** p ≤ 0.001.
Cancers 2020, 12, x FOR PEER REVIEW 13 of 24 
 
 
Figure 5. The druggable grade III meningioma proteome. (a) Proteins with increased concordant 
expression in grade III vs. grade I meningiomas also associated with Food and Drug Administration 
(FDA)-approved drugs are displayed. (b) Top 20 concordantly expressed proteins based on average 
rank value and their associated FDA-approved drugs following submission to the drug–gene 




Cancers 2020, 12, 3270 11 of 22
Cancers 2020, 12, x FOR PEER REVIEW 13 of 24 
 
 
Figure 5. The druggable grade III meningioma proteome. (a) Proteins with increased concordant 
expression in grade III vs. grade I meningiomas also associated with Food and Drug Administration 
(FDA)-approved drugs are displayed. (b) Top 20 concordantly expressed proteins based on average 
rank value and their associated FDA-approved drugs following submission to the drug–gene 
interaction database (DGIdb, v3.0). Table S6 provides details of transcripts/proteins associated with 
FDA-approved drugs. 
  
Figure 5. The druggable grade III meningioma proteome. (a) Proteins with increased concordant
expression in grade III vs. grade I meningiomas als associated with Food a d Drug Adminis ration
(FDA)-a proved drugs are displayed. (b) Top 20 concordantly expressed proteins based on average
rank value and their associated FDA-approved drugs following submission to the drug–gene
interaction database (DGIdb, v3.0). Table S6 provides details of transcripts/proteins associated
with FDA-approved drugs.
3. Discussion
Meningioma are the most frequent primary intracranial tumour. Treatment of high-grade
meningioma has remained a challenge due to their aggressive course, tendency to recur and low overall
survival rates [4]. Drugs holding therapeutic efficacy in the treatment of these aggressive tumours
are still lacking [2]. Here, we combined and analysed the transcriptome–proteome data of grade III
meningioma compared to grade I to unravel the diverging molecular landscapes of these tumour
phenotypes and identify potential grade III therapeutic targets and biomarkers. Although previous
studies have provided much insight into the omics characterisation of these tumours [10,22,25],
a comparison of differential expression at the transcript level and protein level, to our knowledge,
has yet to be performed.
We first established transcripts and proteins common to transcriptome and proteome analyses that
were previously published but extended for this study. Next, we integrated transcript and protein LFC
between grade I and grade III meningioma tissues using a rank-based approach. By observing
expression across these two complementary molecular levels, we were able to distinguish
between genes displaying concordant changes in transcript and protein abundance from those
with discordant changes. Such distinction can guide at better understanding the dysregulation of
genes. Following integration, we found 3598 transcripts/proteins to be common among both omics
platforms with LFCs displaying a moderate, although highly significant Pearson’s correlation coefficient
(r = 0.35; p = 3.6 × 10−104). Previous in vitro mRNA/protein abundance studies using mammalian
cancer cell lines, including glioblastoma, epidermoid carcinoma and osteosarcoma, have displayed
correlation coefficients of between 0.58 and 0.63, as well as 0.54, in medulloblastoma when measured
in the same samples [30,31]. The lower correlation coefficient in our study compared to these in vitro
studies was expected, as our analysis was based on tumour tissue samples in contrast to the relatively
homogenous cellular populations observed in cell lines. Further, our cohorts were independent but
comparable in respect to grade composition, and samples from recurrent cases were excluded.
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Among the top genes with concordant upregulated expression at the transcript and proteomic
level in grade III vs. grade I meningiomas was AGR2, a metastatic oncogene coding for the disulfide
isomerase endoplasmic reticulum protein, anterior gradient 2 homolog (AGR2). Overexpression of
AGR2 has been linked to the proliferation, migration and invasion of several cancers [32,33]. Indeed,
AGR2 has previously been implicated as a novel stem cell biomarker overexpressed in a subset of
aggressive primary meningioma cell lines [34]. Hence, combined, these data suggest AGR2 may be a
contributor to an aggressive meningioma phenotype and should be considered as a possible molecular
marker or therapeutic target on the transcript or protein level. Similarly, the fatty acid-binding protein
FABP7 was also among the top concordantly expressed genes with its overexpression previously
reported to enhance the proliferation and migration of many tumour types [35]. Our validation studies
showed FABP7 expression increased by WB but not by IHC in grade III meningioma compared to
grade I. As the lack of detection by the latter method might be explained by the known limits of
IHC quantification, we would not discard FABP7 on this basis. Moreover, two previous studies have
reported a significant correlation between increasing FABP7 expression and increasing meningioma
grade following IHC [36,37]. Taken together, these findings provide a strong rationale to investigate
the potential role of FABP7 in meningioma pathogenesis. Interestingly, FABP7 acts as an intracellular
transporter of the antinociceptive endocannabinoid, anandamide, to the fatty acid amide hydrolase
for its inactivation, which has led to the development of readily available FABP7 inhibitors for their
analgesic and anti-inflammatory properties [38,39]. In tumourigenesis, the molecular mechanisms
surrounding the involvement of FABP7 remain unclear. Yet, following FABP7 depletion in several
cancer cell lines, proliferation and migration are reduced [40–43], inferring that exploring FABP7
inhibitors may hold promise as a future targeted therapy of meningioma.
We also observed concordantly downregulated transcripts/proteins of grade III meningioma
compared to grade I, providing valuable biomarker candidates and insights into tumorigenesis.
Genes found to be downregulated in grade III meningioma with reported tumour suppressor roles
in various other cancers included FBLN1. As an extracellular matrix (ECM) protein of the fibulin
family, FBLN1 functions in the organisation of ECM supramolecular structures, thereby playing a
role in the regulation of cell morphology, growth, adhesion and motility [44]. Downregulation of
FBLN1 expression has been shown to be associated with tumour progression and act as a prognostic
factor in many cancers such as gastric, renal cell carcinoma, hepatocellular carcinoma and lung
adenocarcinoma [45–48]. In meningioma, overexpression of FBLN1 has previously been identified in
the fibroblastic grade I histological subtype, characterised by a rich collagen matrix, when compared
to the grade I meningothelial subtype [11,49]. Moreover, Fevre et al. (2009) suggested FBNL1 acts
as a tumour suppressor in fibroblastic meningioma whilst alternative suppressors are at play in the
meningothelial subtype [11]. Hence, reduced FBLN1 expression in grade III vs. grade I meningiomas
detected in this study supports the notion that loss of this protein may contribute to a malignant
phenotype of these tumours. Interestingly, in many studies, downregulation of FBLN1 results from
hypermethylation of its promoter [46,47], indicating the importance of expanding upon the omics
platforms integrated here to those such as the epigenome, in order to dissect the molecular mechanisms
underlying the observed dysregulation. In addition to FBLN1, we identified concordant downregulation
of LEPR that binds the multifunctional hormone ligand, leptin, primarily synthesised by adipose
tissue [50]. This receptor–ligand complex predominantly acts to regulate adipose tissue mass and energy
homeostasis through various kinase signalling cascades [50]. Although found to be overexpressed in
some cancers [51,52], LEPR expression was downregulated in high grade meningioma in this study as
well as in two previous meningioma studies [12,26]. Mechanisms underlying LEPR downregulation
and its association with increased tumour progression are not yet understood. However, as a prognostic
biomarker of disease aggressiveness, LEPR has also shown promise in several other cancers including
prostate, endometrial and thyroid, indicating that its value in meningioma prognosis ought to be
investigated further [53–55].
Cancers 2020, 12, 3270 13 of 22
Subsequent to exploring concordantly up and downregulated transcripts/proteins, we focused
on those showing discordant expression in grade III vs. grade I meningiomas. As discussed earlier,
changes in transcript and protein abundance generally show only limited correlation. Various biological
and technical parameters influence mRNA–protein correlation such as mRNA degradation rate,
ribosomal density, protein half-life, compartmental transcript sequestration, secondary RNA structure,
measurement error and noise [56,57]. Thus, we elected not to exclude discordant expression as these
trends may also harbour therapeutic targets and reveal further insight into altered gene expression
between low- and high-grade meningioma. Among those transcripts/proteins displaying the strongest
discordant expression with high protein but low transcript LFC in grade III tumours were the
Na+/HCO3- co-transporter SLC4A4, previously shown to contribute to the proliferation, migration and
invasion of a breast cancer cell line [58], and the phosphofurin acidic cluster sorting protein-1, PACS1,
recently revealed to function in the nucleus as an epigenetic regulator to promote oncogenic replication
and progression [58,59]. To further investigate this discordant trend, we hypothesised that tumour
vasculature may play a role in delivering proteins that are not upregulated on the transcript level in the
tissue itself, to the tumour tissue. Intersection of discordant genes with a publicly accessible human
plasma proteome reference set led to the identification of 21 common proteins [28]. We selected four
of these 21 proteins: PACS1, LAMP2, high-temperature requirement A serine peptidase 1 (HTRA1)
and cystatin C (CST3), and validated a significant reduction in transcript LFC for each in grade III vs.
grade I meningiomas by RT-qPCR. HTRA1 is a ubiquitously expressed serine protease known to be
secreted but also found to have an intracellular presence [60]. The role of HTRA1 in cancer has been
defined as both tumour suppressive and pro-oncogenic [60]. In meningioma, Önder et al. (2015) used
IHC to report a correlation of decreasing cytoplasmic HTRA1 expression with increasing grade and
recurrence, proposing its use as a behavioural marker in these tumours [61]. Conversely, our analyses
revealed an opposing trend of increasing protein expression in high-grade meningioma, yet we also
observed downregulation of HTRA1 transcript LFC. Interestingly, a previous study identified HTRA1
expression in the tumour stroma to regulate Notch signalling, thereby coordinating angiogenesis and
enhancing tumour progression [62]. Therefore, in line with our hypothesis, HTRA1 may also derive
from the tumour microenvironment of fast-growing grade III meningioma to promote angiogenesis.
Unlike HTRA1, LAMP2 has remained unreported in meningioma until now. LAMP2 is a major
glycoprotein component of the lysosomal membrane that functions in autophagy and maintaining
lysosomal integrity [63]. Former studies have linked elevated protein expression of LAMP2 to increased
metastatic potential and poor prognosis in malignancies of the colon, prostate and esophagus [64–66].
Here, we again hypothesised increased LAMP2 protein abundance in grade III meningioma may arise
from the plasma, a theory partially supported by Gabriele et al. (2018), who detected a significant
increase in LAMP2 protein in prostate cancer patients’ sera compared to control using glycopeptide
enrichment and targeted LC-MS/MS [67]. Thus, subject to further investigation, discordantly expressed
transcripts/proteins such as HTRA1 and LAMP2 could hold promise as diagnostic blood biomarkers
for high-grade meningioma.
In addition to identifying individual differentially expressed transcripts/proteins in high-grade
meningioma that may be of clinical relevance, we also explored their associated signalling pathways and
cellular localisations. Predominant biological themes arising from concordantly upregulated grade III
transcripts/proteins included metabolic processes, such as the TCA cycle and oxidative phosphorylation,
which were echoed by an enrichment in mitochondrial localisation. To date, few studies have
ventured to define the metabolic profile of meningioma. Yet, Vasudevan et al. (2018) identified
the transcriptome of male patients with high-grade meningioma also to be enriched in metabolic and
oxidative phosphorylation genes following KEGG pathway analysis [25]. Collectively, these findings
warrant investigation into the presence of altered metabolic pathways in meningioma as well as
grade-specific metabolic reprogramming that may be exploited for targeted therapy. Concordantly
upregulated transcripts/proteins were also enriched in pathways and cellular locations related to
RNA metabolism. Interestingly, we previously observed an association with RNA metabolism,
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including ribosomes and splicing, by both global and phosphoproteomic grade III-specific analyses [19].
Furthermore, several individual transcripts/proteins/phosphoproteins reoccurred throughout these
grade III-specific analyses, such as members of the DEAD-box family of RNA helicases, including DDX5,
DDX6 and DDX42, along with components of the spliceosome including SNRPE and SNRPF. Together,
these commonalities reinforce the importance of studying the role of RNA metabolism in meningioma
aggressiveness and may also lead to the discovery of grade-specific splice variants with potential
as biomarkers or therapeutic targets. Concordantly downregulated grade III transcripts/proteins
were enriched in pathways and cellular locations related to cellular adhesion and the immune
system. Interestingly, among genes enriched in the “cell adhesion molecules (CAMs)” pathway
was cell adhesion molecule 1 (CADM1), whose loss of protein expression has formerly been found
to correlate with increasing meningioma grade and reduced patient survival [68]. CADM1 is a
transmembrane glycoprotein with several tumour suppressor roles including modulation of cell
cycle progression, induction of apoptosis, activation of immunosurveillance responses as well as
enhancement of cell–cell adhesion through its extracellular domain [69]. Loss of CADM1 expression
by promoter hypermethylation or loss of heterozygosity (LOH) has been strongly linked to poor
prognosis, tumour progression, invasion and metastasis in many cancers, and has thus become an
attractive diagnostic and prognostic biomarker [69]. Further examination into downregulated cell
adhesion pathways and their components may therefore lead to novel biomarker discoveries, and if
integrated with methylomic profiling could promote the therapeutic use of DNA methyltransferase
inhibitors in high-grade meningiomas.
Finally, we explored abundant grade III proteins already associated with one or more
FDA-approved drugs that could hold therapeutic efficacy against these tumours. Among the 264
concordantly upregulated genes found to be associated with at least one drug were MAOB and RBP1,
upon which we performed validation studies. Here, it is important to note that in the absence of a
combined ranking of LFCs, genes such as MAOB and RBP1 would not have shown enough prominent
differential expression in either dataset alone to warrant their validation, demonstrating the importance
of integrated analyses. While RBP1 did not exhibit a rise in protein expression between grade III and
grade I meningiomas, MAOB presence was found to be higher in grade III tumours by both WB and
IHC. MAOB is a member of the monoamine oxidases family that catalyse the oxidative deamination of
several monoamine neurotransmitters. In glioblastoma, high expression and activity of MAOB has
led to the exploration of an MAOB-activated pro-drug and selective MAOB inhibitors as potential
treatments [70,71]. Although a pathophysiological role of MAOB in high-grade meningiomas has yet
to be determined, its association to 19 FDA-approved drugs suggests MAOB may prove to be a strong
candidate as a molecular target in these tumours.
For the future we anticipate that our integrative approach will be considerably boosted by the
availability of multi-omics data from the same patient cohort. Our current study was conducted on the
basis of data integration over two different cohorts, which introduced additional variability and limited
the fidelity in detection of concordant or discordant changes. Removing the inter-cohort variability
will enable a more accurate dissection of molecular changes of heterogeneous tumour types such
as meningioma grade II tumours. It will also facilitate the identification of prognostic markers that
can stratify samples within the same grade, as our previous study and a recent study by Viaene and
colleagues implied [12,13].
In summary, we performed an integrated multi-omics study comprising transcriptomic and
proteomic data from two independent analyses of meningioma tissue. We identified previously
described, as well as novel, transcripts/proteins with either concordant up- or downregulated differential
expression between grade III and grade I meningiomas. Moreover, we acknowledged discordant
differential expression and suggested an attractive hypothesis explaining the observation of increased
protein abundance despite lower transcript levels for a sub-group of genes. The corresponding
transcript levels were validated for PACS1, LAMP2, HTRA1 and CST3 in meningioma tissue.
Prospective proteomic studies of meningioma patient plasma will be required to further strengthen the
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validity of these potential diagnostic blood markers. Our results also underlined biological themes
such as metabolic reprogramming, RNA metabolism, immune regulation and cellular adhesion
that, with in-depth evaluation, may elucidate targetable pathways in high-grade meningiomas.
Lastly, we revealed a substantial amount of concordantly upregulated proteins to be associated with
one or more FDA-approved drugs, among which was the validated protein, MAOB, encouraging drug
repurposing for meningioma treatment. Overall, we demonstrate the added value gained by combining
independent omics datasets to enhance our current view of the molecular landscape of meningioma
and to highlight candidates, which upon further investigation, may harbour potential as biomarkers or
therapeutic targets of grade III meningioma.
4. Materials and Methods
4.1. Data Acquisition and Processing
Transcriptome and proteome data of meningioma tissue from two independent studies were
integrated in the current analysis. The transcriptomic dataset produced by Schmidt et al. (2016) was
accessed via the NCBI Gene Expression Omnibus under the GEO accession number GSE74385 and
covered a microarray analysis of 62 meningioma tissues encompassing all WHO grades obtained using
the Human HT-12 v4 BeadChip array (illumina®) [12]. Ten additional meningioma tissues were obtained
under the GEO accession number GSE149923 and combined dataset vsn normalised using the vsn
package (v3.50.0) in the R (v3.5.3) programming environment. Meningiomas were further subgrouped
based on their tendency to recur: NR = no recurrence observed within a period of at least 36 months;
R = recurrence of the same WHO grade following complete resection; M = malignant progression
of tumour with recurrence at a higher WHO grade following complete resection; NA = no further
follow-up available or incomplete resection. For the present study, we compared the transcriptome of
primary meningioma grade I NR (n = 13) (referred to as grade I for the purposes of this study) with that
of all primary meningioma grade III (n = 20). LFC and adjusted p-values were retrieved between both
groups by model fit and contrasts using the limma R package (v3.34.8). The global proteomics dataset
produced by Dunn et al. (2018) (PRIDE repository: PXD007073) using LC–MS/MS was processed
as previously described [19]. Label-free quantification (LFQ) values were log transformed and LFC
between grade III (n = 6) and grade I meningioma (n = 8) calculated in R (v3.5.1). Tumours were
classified by grade according to the 2007 WHO Classification of Tumours of the Central Nervous
System. Clinical and histological details of the meningioma specimens analysed in the transcriptomic
and proteomic studies are presented in Table S1.
Density plot displaying the distribution of transcriptomic and proteomic LFC of grade III vs. grade I
meningiomas was generated in R covering LFC values for 31,385 transcripts and 3846 proteins.
UniProt IDs were mapped to corresponding Entrez Gene IDs using the annotation provided in the
Bioconductor org.Hs.eg.db package (v3.10). UniProt IDs that could not directly be mapped were
alternatively converted to HUGO Gene Nomenclature Committee (HGNC) IDs and then to Entrez Gene
IDs by the HGNC database. Subsequently, Entrez Gene IDs common to both datasets were identified.
Due to substantial differences observed from the underlying distribution of transcriptomic or proteomic
LFC values, a rank-based approach was used to compare transcriptomic and proteomic changes [72].
To determine transcripts/proteins with concordant expression, we first ranked transcript and protein
LFC values separately in descending order (highest LFC assigned rank of 1) followed by calculating
the average rank. Concordant upregulation was indicated by a low average rank while a high average
rank pointed to concordant downregulation. Discordant protein expression was identified as follows:
protein LFC values were ranked in ascending order (lowest LFC assigned rank of 1), whereas transcript
LFC values ranked in descending order (as for concordant expression). After calculating the average
rank, we observed low average ranks for genes whose corresponding proteins were downregulated
while their transcripts were upregulated. In contrast, large average ranks were representative of genes
with upregulated proteins and downregulated transcripts.
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A transcriptome vs. proteome LFC scatterplot was created and Pearson’s correlation coefficient
determined using the basic R functions. Discordantly expressed proteins were intersected with the
published Human Plasma Peptide Atlas consisting of 1929 canonical protein sequences to identify those
also present in human plasma [28]. To identify genes targeted by FDA-approved drugs, gene symbols
were submitted to the drug–gene interaction database (DGIdb) (v3.0, www.dgidb.org) and the
“Food and Drug Administration (FDA) approved” filter was applied [29].
4.2. Functional Enrichment Analyses
Enrichment of biological processes and pathways was investigated based on gene annotation
obtained using Gene Set Enrichment Analysis (GSEA) (v4.0.3) of the Kyoto Encyclopaedia of Genes
and Genomes (KEGG) and Gene Ontology (GO) databases. To assess whether gene sets defining
biological processes or pathways showed a tendency for up or downregulation at the transcriptomic or
proteomic level, GSEA was applied to pre-ranked lists of genes or proteins [73]. Statistical significance
was estimated using a background set of 1000 random permutations. KEGG pathways and GO terms
of transcripts and proteins were considered significantly enriched with false discovery rate (FDR) < 0.2
and visualised as bubble plots using the ggplot2 R package (v3.2.1). For KEGG pathway enrichment,
disease-specific pathways were excluded from the analysis to facilitate focus on enriched signalling
and metabolic pathways with more biological relevance to meningioma pathology.
4.3. Clinical Material
Anonymised meningioma samples under the “J” series were provided by the BRain Archive
and Information Network (BRAIN UK) under ethical approval by the South West research ethics
committee (REC No: 14/SC/0098; IRAS project ID: 143874, BRAIN UK Ref: 15/011). Anonymised “MN”
meningioma samples were collected under ethical approval by the South West research ethics
committee (REC No: 14/SW/0119; IRAS project ID: 153351) and local research and development
approval (Plymouth Hospitals NHS Trust: R&D No: 14/P/056 and North Bristol NHS Trust: R&D No:
3458). Clinical and histological details of the meningioma specimens analysed in the validation studies
are presented in Table S1.
4.4. Cell Culture and Western Blotting
Human meningeal cells (HMC) were obtained from ScienCell™ and cultured in the manufacturer’s
recommended medium and growth supplements at 37 ◦C in humidified 5% CO2. Cells and meningioma
tissue were lysed as previously described [19] and protein concentration determined using the Pierce™
BCA Protein Assay Kit (Thermo Fisher Scientific, Oxford, UK). Western blotting was performed by
separating proteins on 8% or 15% Laemmli SDS-PAGE, depending upon the molecular weight of the
protein of interest and proteins transferred to a polyvinylidene difluoride membrane (Immun-Blot®
PVDF membrane, Bio-Rad, London, UK). Membranes were blocked for 1 hr at room temperature
with 5% skimmed milk in phosphate buffered saline (PBS) with 0.05% Tween-20, before incubation
with specific primary antibodies overnight (O/N) at 4 ◦C. Primary antibody details are listed in
Table S2. Specific antigen–antibody interaction was detected with anti-mouse and anti-rabbit secondary
antibodies conjugated to horseradish peroxidise (Bio-Rad). Detection was achieved using the ECL or
ECL Plus Western Blotting substrate (Pierce). Membranes were exposed to Amersham Hyperfilm
ECL (GE Healthcare Life Sciences, Chalfont St Giles, UK). Films were scanned at a resolution of
600 dpi using a HP Scanjet 2400. Immunoreactive bands were quantified using the ImageJ processing
program and each band normalised to corresponding GAPDH loading control values. The average
value for grade I samples was then calculated and taken as the reference value of one for quantification.
All samples were each divided by the average grade I value. Average quantification values for grade III
meningiomas were then plotted in a bar chart representing expression fold change (FC) vs. grade I = 1.
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4.5. Immunohistochemistry
Four-micrometre formalin-fixed paraffin-embedded sections were de-waxed, rehydrated and
incubated with primary antibodies at room temperature O/N using antigen retrieval methods as
previously described [74]. Primary antibody details are listed in Table S2. Proteins were visualised with
the Vectastain Universal Elite ABC kit (Vector Laboratories Ltd., Burlingame, CA, USA). Slides were
counterstained with haematoxylin (Sigma-Aldrich, Gillingham, UK). As a control, sections were
incubated with omission of the primary antibody. Immunohistochemical results were reviewed by
consultant neuropathologist, Hilton, D.A. Semi-quantitative assessment of staining intensity was
scored as follows: 0 if negative; 1 if low immunoreactivity; 2 if moderate; 3 if high.
4.6. RNA Isolation and Quantitative PCR
Total RNA was extracted from HMC and meningioma tissue using the QIAzol® Lysis Reagent
(Qiagen, Manchester, UK) according to the manufacturer’s instructions. RNA quality and concentration
were assessed using the NanoDrop™ 2000 (Thermo Fisher Scientific, Oxford, UK). One µg of total RNA
was reverse transcribed using a High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems™,
Thermo Fisher Scientific, Oxford, UK). Quantitative PCR (qPCR) was performed on a Real-Time qPCR
LightCycler® 480 System (Roche, Welwyn Garden City, UK) using TaqMan™ Fast Advanced Master
Mix and the corresponding TaqMan® Gene Expression Assay (Assay IDs: CST3 Hs00969174_m1;
PACS1 Hs00216026_m1; LAMP2 Hs00174474_m1; HTRA1 Hs01016151_m1; GAPDH Hs02786624_g1)
(Applied Biosystems™, Thermo Fisher Scientific, Oxford, UK). Thermal cycling conditions were as
follows: 2 min. at 95 ◦C, 45 cycles of amplification with denaturation at 95 ◦C for 15 sec and annealing
and extension at 60 ◦C for 1 min, and cooling at 40 ◦C for 30 s. Relative gene expression was analysed in
triplicate using the 2−∆∆CT method normalised to GAPDH and relative to HMC [75]. A Mann–Whitney
test was performed using GraphPad Prism version 5.00 for Windows to determine the significance of
changes in relative expression between grade I and grade III meningiomas for each gene.
5. Conclusions
Here, we present for the first time the integrated transcriptome–proteome landscape of aggressive
grade III meningiomas compared to benign grade I meningiomas. Dataset integration led to the
identification of 3598 shared transcripts and proteins. Concordant and discordant differential expression
analyses revealed proteins including MAOB, PACS1, LAMP2, HTRA1 and CST3 to show potential as
grade III-specific biomarkers or therapeutic targets. In addition, we detected consistent enrichment
in pathways related to energy and RNA metabolism across transcript and protein levels, whilst
concordantly downregulated transcripts/proteins were associated with immune regulation and cellular
adhesion. Further studies are warranted to determine the role and therapeutic plausibility of these
proteins and pathways in grade III meningiomas.
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J10, Figure S3: Uncropped Western blot gels for Figure 4A, Table S1: Clinical and histological data of the
meningioma specimens analysed in either the microarray or LC-MS/MS discovery sets and those analysed in
the independent validation studies, Table S2: Primary antibody specifications used in Western blotting and
immunohistochemistry, Table S3: (A): Transcript and protein ranking based on grade III vs. grade I meningioma
LFC, (B): Discordant transcriptome–proteome expression based on GIII vs. GI meningioma LFC, (C): Discordantly
expressed proteins identified in plasma, Table S4: (A): Overlapping KEGG pathway enrichment analysis of
transcripts and proteins, (B): Overlapping Hallmark gene sets enrichment analysis of transcripts and proteins,
Table S5: Semi-quantitative scoring of immunohistochemical staining for validation of concordantly expressed
proteins, Table S6: (A): Genes predicted to interact with FDA-approved drugs (grade III vs. grade I meningioma
LFC), (B): Discordantly expressed proteins identified in plasma and their predicted interaction with FDA-approved
drugs, (C): Details of FDA-approved drugs predicted to interact with genes of the transcriptome–proteome
GIII vs. GI meningioma dataset.
Cancers 2020, 12, 3270 18 of 22
Author Contributions: Conceptualisation, C.O.H. and M.E.F.; methodology, M.E.F., V.P.L., J.D., C.O.H., R.W.
and C.H.-M.; software, M.E.F. and V.P.L.; validation, J.D.; formal analysis, M.E.F., V.P.L., J.D., D.A.H. and R.W.;
resources, C.O.H. and C.H.-M.; data curation, J.D., V.P.L. and R.W.; writing—original draft preparation, J.D.,
M.E.F. and V.P.L.; writing—review and editing, J.D., C.O.H., M.E.F. and R.W.; visualisation, J.D., V.P.L. and M.E.F.;
supervision, M.E.F., C.O.H. and C.H.-M.; project administration, C.O.H.; funding acquisition, C.O.H. All authors
have read and agreed to the published version of the manuscript.
Funding: This research was funded by Brain Tumour Research, C. O. Hanemann.
Conflicts of Interest: The authors declare no conflict of interest. The funders had no role in the design of the
study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to
publish the results.
References
1. Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K. WHO Classification of Tumours of the Central Nervous
System, 4th ed.; International Agency for Research on Cancer: Lyon, France, 2016; Volume 1, p. 408.
2. Marosi, C.; Hassler, M.; Roessler, K.; Reni, M.; Sant, M.; Mazza, E.; Vecht, C. Meningioma. Crit. Rev.
Oncol. Hematol. 2008, 67, 153–171. [CrossRef] [PubMed]
3. Apra, C.; Peyre, M.; Kalamarides, M. Current treatment options for meningioma. Expert Rev. Neurother. 2018,
18, 241–249. [CrossRef] [PubMed]
4. Brodbelt, A.R.; Barclay, M.E.; Greenberg, D.; Williams, M.; Jenkinson, M.D.; Karabatsou, K. The outcome
of patients with surgically treated meningioma in England: 1999-2013. A cancer registry data analysis.
Br. J. Neurosurg. 2019, 33, 641–647. [CrossRef]
5. Peyre, M.; Gauchotte, G.; Giry, M.; Froehlich, S.; Pallud, J.; Graillon, T.; Bielle, F.; Cazals-Hatem, D.; Varlet, P.;
Figarella-Branger, D.; et al. De novo and secondary anaplastic meningiomas: A study of clinical and
histomolecular prognostic factors. Neuro. Oncol. 2018, 20, 1113–1121. [CrossRef]
6. Abedalthagafi, M.; Bi, W.L.; Aizer, A.A.; Merrill, P.H.; Brewster, R.; Agarwalla, P.K.; Listewnik, M.L.;
Dias-Santagata, D.; Thorner, A.R.; Van Hummelen, P.; et al. Oncogenic PI3K mutations are as common as
AKT1 and SMO mutations in meningioma. Neuro. Oncol. 2016, 18, 649–655. [CrossRef]
7. Brastianos, P.K.; Horowitz, P.M.; Santagata, S.; Jones, R.T.; McKenna, A.; Getz, G.; Ligon, K.L.; Palescandolo, E.;
Van Hummelen, P.; Ducar, M.D.; et al. Genomic sequencing of meningiomas identifies oncogenic SMO and
AKT1 mutations. Nat. Genet. 2013, 45, 285–289. [CrossRef] [PubMed]
8. Clark, V.E.; Erson-Omay, E.Z.; Serin, A.; Yin, J.; Cotney, J.; Ozduman, K.; Avsar, T.; Li, J.; Murray, P.B.;
Henegariu, O.; et al. Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1,
and SMO. Science 2013, 339, 1077–1080. [CrossRef] [PubMed]
9. Clark, V.E.; Harmanci, A.S.; Bai, H.; Youngblood, M.W.; Lee, T.I.; Baranoski, J.F.; Ercan-Sencicek, A.G.;
Abraham, B.J.; Weintraub, A.S.; Hnisz, D.; et al. Recurrent somatic mutations in POLR2A define a distinct
subset of meningiomas. Nat. Genet. 2016, 48, 1253–1259. [CrossRef]
10. Collord, G.; Tarpey, P.; Kurbatova, N.; Martincorena, I.; Moran, S.; Castro, M.; Nagy, T.; Bignell, G.; Maura, F.;
Young, M.D.; et al. An integrated genomic analysis of anaplastic meningioma identifies prognostic molecular
signatures. Sci. Rep. 2018, 8, 13537. [CrossRef] [PubMed]
11. Fevre-Montange, M.; Champier, J.; Durand, A.; Wierinckx, A.; Honnorat, J.; Guyotat, J.; Jouvet, A. Microarray
gene expression profiling in meningiomas: Differential expression according to grade or histopathological
subtype. Int. J. Oncol. 2009, 35, 1395–1407. [CrossRef] [PubMed]
12. Schmidt, M.; Mock, A.; Jungk, C.; Sahm, F.; Ull, A.T.; Warta, R.; Lamszus, K.; Gousias, K.; Ketter, R.;
Roesch, S.; et al. Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR as
prognostic biomarkers independent of WHO grade. Oncotarget 2016, 7, 14551–14568. [CrossRef]
13. Viaene, A.N.; Zhang, B.; Martinez-Lage, M.; Xiang, C.; Tosi, U.; Thawani, J.P.; Gungor, B.; Zhu, Y.;
Roccograndi, L.; Zhang, L.; et al. Transcriptome signatures associated with meningioma progression.
Acta Neuropathol. Commun. 2019, 7, 67. [CrossRef] [PubMed]
14. Watson, M.A.; Gutmann, D.H.; Peterson, K.; Chicoine, M.R.; Kleinschmidt-DeMasters, B.K.; Brown, H.G.;
Perry, A. Molecular characterization of human meningiomas by gene expression profiling using high-density
oligonucleotide microarrays. Am. J. Pathol. 2002, 161, 665–672. [CrossRef]
Cancers 2020, 12, 3270 19 of 22
15. Wrobel, G.; Roerig, P.; Kokocinski, F.; Neben, K.; Hahn, M.; Reifenberger, G.; Lichter, P. Microarray-based
gene expression profiling of benign, atypical and anaplastic meningiomas identifies novel genes associated
with meningioma progression. Int. J. Cancer 2005, 114, 249–256. [CrossRef]
16. Diez, P.; Droste, C.; Degano, R.M.; Gonzalez-Munoz, M.; Ibarrola, N.; Perez-Andres, M.; Garin-Muga, A.;
Segura, V.; Marko-Varga, G.; LaBaer, J.; et al. Integration of Proteomics and Transcriptomics Data Sets for the
Analysis of a Lymphoma B-Cell Line in the Context of the Chromosome-Centric Human Proteome Project.
J. Proteome Res. 2015, 14, 3530–3540. [CrossRef]
17. Latosinska, A.; Makridakis, M.; Frantzi, M.; Borras, D.M.; Janssen, B.; Mullen, W.; Zoidakis, J.;
Merseburger, A.S.; Jankowski, V.; Mischak, H.; et al. Integrative analysis of extracellular and intracellular
bladder cancer cell line proteome with transcriptome: Improving coverage and validity of -omics findings.
Sci. Rep. 2016, 6, 25619. [CrossRef]
18. Schwanhausser, B.; Busse, D.; Li, N.; Dittmar, G.; Schuchhardt, J.; Wolf, J.; Chen, W.; Selbach, M. Global
quantification of mammalian gene expression control. Nature 2011, 473, 337–342. [CrossRef] [PubMed]
19. Dunn, J.; Ferluga, S.; Sharma, V.; Futschik, M.; Hilton, D.A.; Adams, C.L.; Lasonder, E.; Hanemann, C.O.
Proteomic analysis discovers the differential expression of novel proteins and phosphoproteins in meningioma
including NEK9, HK2 and SET and deregulation of RNA metabolism. EBioMedicine 2019, 40, 77–91. [CrossRef]
20. Parada, C.A.; Osbun, J.; Kaur, S.; Yakkioui, Y.; Shi, M.; Pan, C.; Busald, T.; Karasozen, Y.; Gonzalez-Cuyar, L.F.;
Rostomily, R.; et al. Kinome and phosphoproteome of high-grade meningiomas reveal AKAP12 as a central
regulator of aggressiveness and its possible role in progression. Sci. Rep. 2018, 8, 2098. [CrossRef]
21. Misra, B.B.; Langefeld, C.D.; Olivier, M.; Cox, L.A. Integrated Omics: Tools, Advances, and Future Approaches.
J. Mol. Endocrinol. 2019, 62, R21–R45. [CrossRef]
22. Sahm, F.; Schrimpf, D.; Stichel, D.; Jones, D.T.W.; Hielscher, T.; Schefzyk, S.; Okonechnikov, K.; Koelsche, C.;
Reuss, D.E.; Capper, D.; et al. DNA methylation-based classification and grading system for meningioma:
A multicentre, retrospective analysis. Lancet Oncol. 2017, 18, 682–694. [CrossRef]
23. Harmanci, A.S.; Youngblood, M.W.; Clark, V.E.; Coskun, S.; Henegariu, O.; Duran, D.; Erson-Omay, E.Z.;
Kaulen, L.D.; Lee, T.I.; Abraham, B.J.; et al. Integrated genomic analyses of de novo pathways underlying
atypical meningiomas. Nat. Commun. 2018, 9, 16215. [CrossRef] [PubMed]
24. Paramasivam, N.; Hubschmann, D.; Toprak, U.H.; Ishaque, N.; Neidert, M.; Schrimpf, D.; Stichel, D.;
Reuss, D.; Sievers, P.; Reinhardt, A.; et al. Mutational patterns and regulatory networks in epigenetic
subgroups of meningioma. Acta Neuropathol. 2019, 138, 295–308. [CrossRef]
25. Vasudevan, H.N.; Braunstein, S.E.; Phillips, J.J.; Pekmezci, M.; Tomlin, B.A.; Wu, A.; Reis, G.F.; Magill, S.T.;
Zhang, J.; Feng, F.Y.; et al. Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription
Factor for Meningioma Proliferation. Cell Rep. 2018, 22, 3672–3683. [CrossRef] [PubMed]
26. Menghi, F.; Orzan, F.N.; Eoli, M.; Farinotti, M.; Maderna, E.; Pisati, F.; Bianchessi, D.; Valletta, L.; Lodrini, S.;
Galli, G.; et al. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma
recurrence. Oncologist 2011, 16, 1440–1450. [CrossRef]
27. Miller, R., Jr.; DeCandio, M.L.; Dixon-Mah, Y.; Giglio, P.; Vandergrift, W.A., 3rd; Banik, N.L.; Patel, S.J.;
Varma, A.K.; Das, A. Molecular Targets and Treatment of Meningioma. J. Neurol. Neurosurg. 2014, 1, 1.
28. Farrah, T.; Deutsch, E.W.; Omenn, G.S.; Campbell, D.S.; Sun, Z.; Bletz, J.A.; Mallick, P.; Katz, J.E.; Malmstrom, J.;
Ossola, R.; et al. A high-confidence human plasma proteome reference set with estimated concentrations in
PeptideAtlas. Mol. Cell. Proteom. 2011, 10, M110.006353. [CrossRef]
29. Cotto, K.C.; Wagner, A.H.; Feng, Y.Y.; Kiwala, S.; Coffman, A.C.; Spies, G.; Wollam, A.; Spies, N.C.;
Griffith, O.L.; Griffith, M. DGIdb 3.0: A redesign and expansion of the drug-gene interaction database.
Nucleic Acids Res. 2018, 46, D1068–D1073. [CrossRef]
30. Lundberg, E.; Fagerberg, L.; Klevebring, D.; Matic, I.; Geiger, T.; Cox, J.; Algenas, C.; Lundeberg, J.;
Mann, M.; Uhlen, M. Defining the transcriptome and proteome in three functionally different human cell
lines. Mol. Syst. Biol. 2010, 6, 450. [CrossRef]
31. Vogel, C.; Abreu Rde, S.; Ko, D.; Le, S.Y.; Shapiro, B.A.; Burns, S.C.; Sandhu, D.; Boutz, D.R.; Marcotte, E.M.;
Penalva, L.O. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance
variation in a human cell line. Mol. Syst. Biol. 2010, 6, 400. [CrossRef]
32. Dahal Lamichane, B.; Jung, S.Y.; Yun, J.; Kang, S.; Kim, D.Y.; Lamichane, S.; Kim, Y.J.; Park, J.H.; Jang, W.B.;
Ji, S.T.; et al. AGR2 is a target of canonical Wnt/beta-catenin signaling and is important for stemness
maintenance in colorectal cancer stem cells. Biochem. Biophys. Res. Commun. 2019, 515, 600–606. [CrossRef]
Cancers 2020, 12, 3270 20 of 22
33. Sung, H.Y.; Choi, E.N.; Lyu, D.; Park, A.K.; Ju, W.; Ahn, J.H. Aberrant hypomethylation-mediated AGR2
overexpression induces an aggressive phenotype in ovarian cancer cells. Oncol. Rep. 2014, 32, 815–820.
[CrossRef] [PubMed]
34. Khan, I.; Baeesa, S.; Bangash, M.; Schulten, H.J.; Alghamdi, F.; Qashqari, H.; Madkhali, N.; Carracedo, A.;
Saka, M.; Jamal, A.; et al. Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive
primary meningioma cell lines. Cancer Cell Int. 2017, 17, 72. [CrossRef]
35. Kagawa, Y.; Umaru, B.A.; Ariful, I.; Shil, S.K.; Miyazaki, H.; Yamamoto, Y.; Ogata, M.; Owada, Y. Role of
FABP7 in tumor cell signaling. Adv. Biol. Regul. 2019, 71, 206–218. [CrossRef]
36. Jiang, J.; Lin, C.; Liu, N.; Zhang, Z.; Sun, Y.; Fang, X.; Qi, J. The expression of fatty acid metabolism-associated
proteins is correlated with the prognosis of meningiomas. APMIS 2013, 121, 997–1003. [CrossRef]
37. Panagopoulos, A.T.; Lancellotti, C.L.; Veiga, J.C.; de Aguiar, P.H.; Colquhoun, A. Expression of cell adhesion
proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic
meningiomas. J. Neurooncol. 2008, 89, 73–87. [CrossRef]
38. Berger, W.T.; Ralph, B.P.; Kaczocha, M.; Sun, J.; Balius, T.E.; Rizzo, R.C.; Haj-Dahmane, S.; Ojima, I.;
Deutsch, D.G. Targeting fatty acid binding protein (FABP) anandamide transporters—A novel strategy
for development of anti-inflammatory and anti-nociceptive drugs. PLoS ONE 2012, 7, e50968. [CrossRef]
[PubMed]
39. Kaczocha, M.; Rebecchi, M.J.; Ralph, B.P.; Teng, Y.H.; Berger, W.T.; Galbavy, W.; Elmes, M.W.; Glaser, S.T.;
Wang, L.; Rizzo, R.C.; et al. Inhibition of fatty acid binding proteins elevates brain anandamide levels and
produces analgesia. PLoS ONE 2014, 9, e94200. [CrossRef] [PubMed]
40. Liu, R.Z.; Graham, K.; Glubrecht, D.D.; Lai, R.; Mackey, J.R.; Godbout, R. A fatty acid-binding protein
7/RXRbeta pathway enhances survival and proliferation in triple-negative breast cancer. J. Pathol. 2012, 228,
310–321. [CrossRef]
41. Slipicevic, A.; Jorgensen, K.; Skrede, M.; Rosnes, A.K.; Troen, G.; Davidson, B.; Florenes, V.A. The fatty acid
binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells. BMC Cancer 2008, 8,
276. [CrossRef] [PubMed]
42. Tian, W.; Shi, J.; Qin, J.; Jin, G.; Han, X.; Li, H. Brain lipid binding protein mediates the proliferation of human
glioblastoma cells by regulating ERK1/2 signaling pathway in vitro. Vitr. Cell. Dev. Biol. Anim. 2018, 54,
156–162. [CrossRef]
43. Tolle, A.; Krause, H.; Miller, K.; Jung, K.; Stephan, C. Importance of braintype fatty acid binding protein for
cell-biological processes in human renal carcinoma cells. Oncol. Rep. 2011, 25, 1307–1312. [CrossRef]
44. Timpl, R.; Sasaki, T.; Kostka, G.; Chu, M.L. Fibulins: A versatile family of extracellular matrix proteins.
Nat. Rev. Mol. Cell Biol. 2003, 4, 479–489. [CrossRef]
45. Cui, Y.; Liu, J.; Yin, H.B.; Liu, Y.F.; Liu, J.H. Fibulin-1 functions as a prognostic factor in lung adenocarcinoma.
Jpn. J. Clin. Oncol. 2015, 45, 854–859. [CrossRef]
46. Feng, L.; Yao, C.; Li, P.; Feng, Y.; Wang, F.; Liu, Y.F.; Guo, Y.B.; Mao, Q.S.; Xue, W.J. Low expression of
fibulin-1 correlates with unfavorable prognosis in gastric cancer. Tumour Biol. 2016, 37, 9399–9410. [CrossRef]
[PubMed]
47. Kanda, M.; Nomoto, S.; Okamura, Y.; Hayashi, M.; Hishida, M.; Fujii, T.; Nishikawa, Y.; Sugimoto, H.;
Takeda, S.; Nakao, A. Promoter hypermethylation of fibulin 1 gene is associated with tumor progression in
hepatocellular carcinoma. Mol. Carcinog. 2011, 50, 571–579. [CrossRef]
48. Xiao, W.; Wang, J.; Li, H.; Guan, W.; Xia, D.; Yu, G.; Xiao, H.; Lang, B.; Ma, X.; Liu, J.; et al. Fibulin-1 is
down-regulated through promoter hypermethylation and suppresses renal cell carcinoma progression.
J. Urol. 2013, 190, 291–301. [CrossRef]
49. Kalamarides, M.; Stemmer-Rachamimov, A.O.; Niwa-Kawakita, M.; Chareyre, F.; Taranchon, E.; Han, Z.Y.;
Martinelli, C.; Lusis, E.A.; Hegedus, B.; Gutmann, D.H.; et al. Identification of a progenitor cell of origin
capable of generating diverse meningioma histological subtypes. Oncogene 2011, 30, 2333–2344. [CrossRef]
[PubMed]
50. Zhang, Y.; Chua, S., Jr. Leptin Function and Regulation. Compr. Physiol. 2017, 8, 351–369. [CrossRef]
51. Han, G.; Li, Y.; Cao, Y.; Yue, Z.; Zhang, Y.; Wang, L.; Liu, J. Overexpression of leptin receptor in human
glioblastoma: Correlation with vasculogenic mimicry and poor prognosis. Oncotarget 2017, 8, 58163–58171.
[CrossRef]
Cancers 2020, 12, 3270 21 of 22
52. Vuletic, M.S.; Milosevic, V.S.; Jancic, S.A.; Zujovic, J.T.; Krstic, M.S.; Vukmirovic, F.C. Clinical significance of
Leptin receptor (LEPR) and Endoglin (CD105) expressions in colorectal adenocarcinoma. J. BU ON 2019, 24,
2448–2457.
53. Fan, Y.L.; Li, X.Q. Expression of leptin and its receptor in thyroid carcinoma: Distinctive prognostic
significance in different subtypes. Clin. Endocrinol. 2015, 83, 261–267. [CrossRef]
54. Osorio, C.F.; Souza, D.B.; Gallo, C.B.; Costa, W.S.; Sampaio, F.J. Leptin and leptin receptor expressions in
prostate tumors may predict disease aggressiveness? Acta Cir. Bras. 2014, 29(Suppl. 3), 44–48. [CrossRef]
55. Yuan, S.S.; Tsai, K.B.; Chung, Y.F.; Chan, T.F.; Yeh, Y.T.; Tsai, L.Y.; Su, J.H. Aberrant expression and possible
involvement of the leptin receptor in endometrial cancer. Gynecol. Oncol. 2004, 92, 769–775. [CrossRef]
56. Kumar, D.; Bansal, G.; Narang, A.; Basak, T.; Abbas, T.; Dash, D. Integrating transcriptome and proteome
profiling: Strategies and applications. Proteomics 2016, 16, 2533–2544. [CrossRef]
57. Maier, T.; Guell, M.; Serrano, L. Correlation of mRNA and protein in complex biological samples. FEBS Lett.
2009, 583, 3966–3973. [CrossRef]
58. Parks, S.K.; Pouyssegur, J. The Na(+)/HCO3(-) Co-Transporter SLC4A4 Plays a Role in Growth and Migration
of Colon and Breast Cancer Cells. J. Cell. Physiol. 2015, 230, 1954–1963. [CrossRef]
59. Mani, C.; Tripathi, K.; Luan, S.; Clark, D.W.; Andrews, J.F.; Vindigni, A.; Thomas, G.; Palle, K.
The multifunctional protein PACS-1 is required for HDAC2- and HDAC3-dependent chromatin maturation
and genomic stability. Oncogene 2020, 39, 2583–2596. [CrossRef] [PubMed]
60. Li, Y.; Yuan, J.; Rothzerg, E.; Wu, X.; Xu, H.; Zhu, S.; Xu, J. Molecular structure and the role of high-temperature
requirement protein 1 in skeletal disorders and cancers. Cell Prolif. 2020, 53, e12746. [CrossRef] [PubMed]
61. Onder, E.; Arikok, A.T.; Seckin, H.; Alper, M. Decrease in serine protease HtrA1 expression correlates with
grade and recurrence in meningiomas. Adv. Med. Sci. 2015, 60, 139–143. [CrossRef]
62. Klose, R.; Adam, M.G.; Weis, E.M.; Moll, I.; Wustehube-Lausch, J.; Tetzlaff, F.; Oka, C.; Ehrmann, M.;
Fischer, A. Inactivation of the serine protease HTRA1 inhibits tumor growth by deregulating angiogenesis.
Oncogene 2018, 37, 4260–4272. [CrossRef] [PubMed]
63. Saftig, P.; Klumperman, J. Lysosome biogenesis and lysosomal membrane proteins: Trafficking meets
function. Nat. Rev. Mol. Cell Biol. 2009, 10, 623–635. [CrossRef] [PubMed]
64. Li, L.; Wang, W.; Zhang, R.; Liu, J.; Yu, J.; Wu, X.; Xu, Y.; Ma, M.; Huang, J. High expression of LAMP2
predicts poor prognosis in patients with esophageal squamous cell carcinoma. Cancer Biomark. 2017, 19,
305–311. [CrossRef]
65. Morell, C.; Bort, A.; Vara-Ciruelos, D.; Ramos-Torres, A.; Altamirano-Dimas, M.; Diaz-Laviada, I.;
Rodriguez-Henche, N. Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine
Differentiation of Prostate Cancer LNCaP Cells. PLoS ONE 2016, 11, e0162977. [CrossRef]
66. Saitoh, O.; Wang, W.C.; Lotan, R.; Fukuda, M. Differential glycosylation and cell surface expression of
lysosomal membrane glycoproteins in sublines of a human colon cancer exhibiting distinct metastatic
potentials. J. Biol. Chem. 1992, 267, 5700–5711.
67. Gabriele, C.; Cantiello, F.; Nicastri, A.; Crocerossa, F.; Russo, G.I.; Cicione, A.; Vartolomei, M.D.; Ferro, M.;
Morgia, G.; Lucarelli, G.; et al. High-throughput detection of low abundance sialylated glycoproteins in
human serum by TiO2 enrichment and targeted LC-MS/MS analysis: Application to a prostate cancer sample
set. Anal. Bioanal. Chem. 2019, 411, 755–763. [CrossRef]
68. Surace, E.I.; Lusis, E.; Murakami, Y.; Scheithauer, B.W.; Perry, A.; Gutmann, D.H. Loss of tumor suppressor in
lung cancer-1 (TSLC1) expression in meningioma correlates with increased malignancy grade and reduced
patient survival. J. Neuropathol. Exp. Neurol. 2004, 63, 1015–1027. [CrossRef] [PubMed]
69. Liang, Q.L.; Chen, G.Q.; Li, Z.Y.; Wang, B.R. Function and histopathology of a cell adhesion molecule TSLC1
in cancer. Cancer Investig. 2011, 29, 107–112. [CrossRef]
70. Marconi, G.D.; Gallorini, M.; Carradori, S.; Guglielmi, P.; Cataldi, A.; Zara, S. The Up-Regulation of Oxidative
Stress as a Potential Mechanism of Novel MAO-B Inhibitors for Glioblastoma Treatment. Molecules 2019,
24, 2005. [CrossRef]
71. Sharpe, M.A.; Livingston, A.D.; Gist, T.L.; Ghosh, P.; Han, J.; Baskin, D.S. Successful Treatment of Intracranial
Glioblastoma Xenografts With a Monoamine Oxidase B-Activated Pro-Drug. EBioMedicine 2015, 2, 1122–1132.
[CrossRef]
Cancers 2020, 12, 3270 22 of 22
72. Becker, R.A.; Chambers, J.M.; Reeve Wilks, A. The New S Language: A Programming Environment for Data
Analysis and Graphics; Wadsworth & Brooks/Cole Advanced Books & Software: Monterey, CA, USA, 1988;
p. 702.
73. Subramanian, A.; Tamayo, P.; Mootha, V.K.; Mukherjee, S.; Ebert, B.L.; Gillette, M.A.; Paulovich, A.;
Pomeroy, S.L.; Golub, T.R.; Lander, E.S.; et al. Gene set enrichment analysis: A knowledge-based approach for
interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 2005, 102, 15545–15550. [CrossRef]
74. Hilton, D.A.; Shivane, A.; Kirk, L.; Bassiri, K.; Enki, D.G.; Hanemann, C.O. Activation of multiple growth
factor signalling pathways is frequent in meningiomas. Neuropathology 2016, 36, 250–261. [CrossRef]
75. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) Method. Methods 2001, 25, 402–408. [CrossRef]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional
affiliations.
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
